Andere Sprachen Rohto Pharmaceutical Co.,Ltd.

Aktien

858075

JP3982400008

4527

Verzögert Japan Exchange Andere Börsenplätze 04:22:37 01.05.2024			% 5 Tage	% 1. Jan.
3.084 ^JPY	+0,03 %		+3,35 %	+8,44 %

04.04.	Mitsui und Rohto kaufen für 594 Mio. $ das chinesische Arzneimittelunternehmen Eu Yan Sang	RE
12.02.	Rohto Pharmaceutical steigert Gewinn in den ersten neun Monaten des Geschäftsjahres um 21% und hebt Ausblick für das Geschäftsjahr an	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen	04.04.
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update	04.04.
Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang	04.04.
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang	04.04.
Rohto Pharmaceutical Co.,Ltd., Mitsui & Co., Ltd. and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.	04.04.
FiNC Technologies Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	28.03.
Rohto Pharmaceutical's Profit Climbs 21% in Fiscal Nine Months, Lifts Fiscal-Year Outlook	12.02.
Alina Vision Pte Ltd. announced that it has received funding from Fred Hollows Foundation, Rohto Pharmaceutical Co.,Ltd., TVM Capital Healthcare Partners	16.01.
Plantex Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd., Dai-ichi Life Holdings, Inc., RealTechJapan LLC.	30.11.
Rohto Pharmaceutical Co.,Ltd.(TSE:4527) added to S&P Japan Mid Cap 100	29.11.
Japanese Shares Close Marginally Higher Monday Ahead of Biden-Xi Meeting	13.11.
Rohto Pharmaceutical’s Attributable Profit Soars 25.8% in Fiscal H1 on Significant Profit Increases Across Categories	13.11.
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024	10.11.
Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023	10.11.
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	10.11.
Australis Scientific Pty Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	25.10.23
Butterfly Pea Laboratory Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd. and other investors.	02.10.23
Rohto Pharmaceutical’s Attributable Profit Rises 30% in Fiscal Q1 due to Significant Sales Increase	25.08.23
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	09.08.23
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	09.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Rohto Pharmaceutical Co.,Ltd.: Pharma-Champion bei rezeptfreien Medikamenten

Am 21. März 2023 um 11:46 Uhr